Alk-Abello ASWBO:ALKB -0.12%65 Quick Ratio is 2.01 as of Mar. 2026, which is 65% above its 10-year median of 1.22. GuruFocus rates WBO:ALKB with a GF Score™ of 65/100 and a GF Value™ of €27.26 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Alk-Abello AS ranks worse than 65.32% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Alk-Abello AS's quick ratio for the quarter that ended in Mar. 2026 was 2.01.
Alk-Abello AS has a quick ratio of 2.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Alk-Abello AS's Quick Ratio or its related term are showing as below:
WBO:ALKB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.81 Med: 1.22 Max: 2.04
Current: 2.01
During the past 13 years, Alk-Abello AS's highest Quick Ratio was 2.04. The lowest was 0.81. And the median was 1.22.
WBO:ALKB's Quick Ratio is ranked worse than 65.32% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs WBO:ALKB: 2.01
Alk-Abello AS (WBO:ALKB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Alk-Abello AS Quick Ratio Related Terms
Alk-Abello AS Quick Ratio Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:ALKB vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Alk-Abello AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Alk-Abello AS's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (WBO:ALKB) has a Quick Ratio of 2.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alk-Abello AS and its competitors. This is 65% above median its historical median of 1.22. Over the past decade, Alk-Abello AS's Quick Ratio has ranged from 0.81 to 2.04. According to the industry distribution chart, Alk-Abello AS ranks #925 out of 1416 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Alk-Abello AS's Quick Ratio too high?
Alk-Abello AS's current Quick Ratio of 2.01 is 65% above median its 10-year median of 1.22. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 2.04. The Biotechnology industry median Quick Ratio is 3.60. Alk-Abello AS's value of 2.01 is 44.2% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #925 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #925 out of 1416 companies for Quick Ratio. This places Alk-Abello AS in the lower half of its industry. The industry median Quick Ratio is 3.60. Alk-Abello AS's value of 2.01 is 44.2% below this benchmark. Historically, Alk-Abello AS's own Quick Ratio has ranged from 0.81 to 2.04 over the past decade. While the company's 10-year median is 1.22 vs. the industry median of 3.60, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Quick Ratio of 2.01 is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Quick Ratio is 2.01, which is 65% above median its own 10-year median of 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (WBO:ALKB) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.26, compared to a current price of €34.22 — trading 25.5% above its estimated fair value. The current Quick Ratio is 2.01, which is 65% above median its 10-year median of 1.22 and 44.2% below the Biotechnology industry median of 3.60. Alk-Abello AS's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Alk-Abello AS (WBO:ALKB), the current Quick Ratio is 2.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (WBO:ALKB) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of €34.22 is trading 25.5% above its estimated GF Value™ of €27.26.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for WBO:ALKB:
Quick Ratio: 2.01 (65% above median its 10-year median of 1.22)
GF Value™: €27.26 vs. price of €34.22 (25.5% above fair value)
Industry Position: 44.2% below the Biotechnology median (#925 of 1416)
No single metric tells the full story. See the WBO:ALKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
65GF Score
Get the complete analysis for WBO:ALKB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ALKB has been successfully added to your 
